An investigation by the NGO OxySuisse has uncovered 29 instances of collaboration between Swiss universities and the tobacco industry since 2019, sparking a debate on academic independence and the ethics of research funding.

"For decades, the tobacco industry has used scientific collaboration to gain legitimacy, minimise the risks of its products, and influence health policies, often in a covert manner."
"The actual number may be higher due to non-disclosure and confidentiality clauses."
Switzerlandās reputation for academic purity is choking on smoke. A damning new investigation by OxySuisse has shattered the illusion of independence, revealing that Switzerland ranks a staggering 99th out of 100 in the 2025 Global Tobacco Industry Interference Index. This abysmal score places our nation among the most vulnerable in the world to corporate manipulation, exposing a systemic failure to protect public health research from commercial predators.
The report uncovers 29 confirmed collaborations between Swiss universities and the tobacco industry since 2019, spanning 16 prestigious institutions. These are not isolated incidents; they represent a pervasive infiltration of our lecture halls and laboratories. From joint doctoral theses to funded workshops, the tobacco industry is weaving itself into the fabric of Swiss higher education. OxySuisse warns that this figure is likely a conservative estimate, with the true extent of the rot hidden behind non-disclosure agreements and confidentiality clauses that keep the public in the dark.
One name dominates this web of influence: Philip Morris International (PMI). Of the 29 collaborations exposed, a massive 23 are directly linked to the tobacco giant. This is not merely participation; it is dominance. PMI has effectively purchased access to Swiss academia, engaging in joint research and teaching assignments that blur the line between objective science and corporate marketing.
The strategy is clear and calculated. By embedding itself within universities of applied sciences, federal institutes, and university hospitals, PMI seeks to scrub its image and buy scientific legitimacy. OxySuisse argues that these partnerships allow the industry to minimize product risks and subtly influence health policies from the inside out. While the world fights nicotine addiction, Swiss institutions are accepting checks from the very architects of the crisis, turning our vaunted research facilities into extensions of the tobacco industry's R&D departments.
When pressed for the truth, Swiss academia didn't just hesitateāit slammed the door. OxySuisse reveals that four major institutions refused to disclose contracts or provide information regarding their industry ties. This stonewalling forced the NGO to launch legal proceedings to pry open the archives. In a victory for public interest, every legal challenge decided so far has gone in favor of the association, supported by cantonal transparency offices that recognize the public's right to know.
This resistance to transparency is damning. If these collaborations were purely for the advancement of science, why hide them? The refusal to publish contracts suggests a keen awareness that these partnerships violate the spirit, if not the letter, of academic ethics. The report ranks institutions based on their transparency, shaming those who choose secrecy over integrity. It is a stark reminder that in the fight for truth, some of our most respected institutions are currently on the wrong side of the barricade.
This is not a new phenomenon; it is a recurring scandal. Switzerland has a dark history of academic complicity, most notably the Rylander affair, where a University of Geneva professor produced research on passive smoking while secretly on Philip Morris's payroll. Similarly, the University of Zurich previously accepted a mandate from PMI to evaluate plain cigarette packagingāa clear conflict of interest.
OxySuisse, backed by international research from the University of Bath and Le Monde, asserts that these are not random ethical lapses. They are part of a systematic, global strategy to distort science. The industry uses these collaborations to manufacture doubt and delay regulation. By funding studies that muddy the waters, they protect their bottom line at the expense of public health. The persistence of these tactics proves that without strict, binding rules, history will continue to repeat itself, with Swiss universities serving as willing pawns.
The time for polite requests is over. OxySuisse is escalating the battle by launching a secure "whistleblower" channel, empowering researchers and university staff to confidentially report ethical violations. This move signals a shift from passive observation to active resistance. The NGO is demanding mandatory transparency for all industry projects and the adoption of binding national ethics rules to close the loopholes that allow these partnerships to fester.
With a Swiss tobacco ad ban set to protect minors starting in 2027, the legislative tide is slowly turning, but academia remains a blind spot. OxySuisse's ultimatum is clear: increased awareness among ethics commissions is no longer enough. We need a firewall between public research and private profit. Until Swiss universities can prove their independence, every study they publish on public health will carry an asteriskāand the faint, lingering scent of tobacco smoke.